Evidence-based treatment of hypertension in patients with type 2 diabetes

Affiliations

Review

A De Vriese. Acta Clin Belg. 2001 Mar-Apr.

. 2001 Mar-Apr;56(2):96-102.

doi: 10.1179/acb.2001.017.

¹ Renal Unit, University Hospital, OK12, De Pintelaan 185, B-9000 Gent, Belgium. an.devriese@rug.ac.be

No abstract available

Similar articles

ARBs for cardiovascular and renal protection in high-risk patients.
Aalbers J. Aalbers J. Cardiovasc J Afr. 2011 Jul-Aug;22(4):224. Cardiovasc J Afr. 2011. PMID: 21881697 No abstract available.
[Management of patients with essential hypertension. Clinical recommendations and economic data. Guidelines April 2000. Recommendations of the ANAES].
Agence Nationale d'Accréditation et d'Evaluation en Santé. Agence Nationale d'Accréditation et d'Evaluation en Santé. J Mal Vasc. 2000 Dec;25(5):366-376. J Mal Vasc. 2000. PMID: 11148400 French. No abstract available.
Is treatment of hypertension with acetylcholine esterase inhibitors (ACEIs) superior to other antihypertensives in preventing significant cardiovascular events and death in patients with type 2 diabetes?
McConaghy JR. McConaghy JR. J Fam Pract. 2000 Nov;49(11):980. J Fam Pract. 2000. PMID: 11093559 No abstract available.
[The pharmacotherapy of arterial hypertension and the prevention of cardiovascular events. From evidence-based medicine to the new therapeutic opportunities].
Taddei S. Taddei S. Recenti Prog Med. 1999 Jan;90(1):4-8. Recenti Prog Med. 1999. PMID: 10193156 Review. Italian. No abstract available.
Cardiovascular and renal disease in untreated and treated hypertension.
Mancia G, Giannattasio C, Pozzi M. Mancia G, et al. Contrib Nephrol. 1994;109:65-9. doi: 10.1159/000423289. Contrib Nephrol. 1994. PMID: 7956231 Review. No abstract available.